Trials / Completed
CompletedNCT03835715
Study With Vortioxetine on Emotional Functioning in Patients With Depression
Interventional, Open-label, Flexible-dose Study of Vortioxetine on Emotional Functioning in Patients With Major Depressive Disorder With Inadequate Response to SSRI/SNRI Treatment
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate effectiveness of flexible dose vortioxetine 10-20 mg/day on emotional functioning in patients with MDD with an inadequate response to SSRIs/SNRIs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vortioxetine | Flexible doses (10-20 mg) of vortioxetine; 10 mg during the first week which may be increased up to 20 mg week 2-8 |
Timeline
- Start date
- 2019-02-05
- Primary completion
- 2020-02-21
- Completion
- 2020-02-21
- First posted
- 2019-02-08
- Last updated
- 2020-03-24
Locations
23 sites across 4 countries: France, Italy, Lithuania, Spain
Source: ClinicalTrials.gov record NCT03835715. Inclusion in this directory is not an endorsement.